Evidence map›Paper›PMID 33364626›Full record

ArticleJournal of life sciences (Westlake Village, Calif.)2020

T cell receptor sequencing in autoimmunity.

Angela M Mitchell, Aaron W Michels

Open access · greenAbstract read
In one paragraph

Article in Journal of life sciences (Westlake Village, Calif.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. CXCR5Frontiers in medicine · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Angela M MitchellBarbara Davis Center for Diabetes, University of Colorado, Aurora, CO, USA, 80045.
Aaron W MichelsBarbara Davis Center for Diabetes, University of Colorado, Aurora, CO, USA, 80045.
University of Colorado Health · US

Funding

University of Colorado Anschutz Medical Campus DRCP30DK116073 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI LORI SUSSEL · 2020 to 2026
$10.8M
Natural History of Pre-Diabetic Autoimmunity (DAISY)R01DK032493 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI REWERS, MARIAN J · 1986 to 2024
$9.3M
Natural History of Pre-diabetic Autoimmunity (DAISY)R37DK032493 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI REWERS, MARIAN J · 2001 to 2010
$8.0M
Multiple Autoantigens/Multiple Epitopes of Type 1DMR01DK032083 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI MICHELS, AARON W · 1986 to 2025
$6.9M
Molecular Dissection of Insulin Targeting in Anti-Islet AutoimmunityR01DK099317 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI AARON W MICHELS, Maki Nakayama · 2013 to 2026
$5.3M
Insulin Specific T Cell Response Shaped by Diabetes Protective MHC Class II MoleculesR01DK108868 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI AARON W MICHELS · 2017 to 2026
$3.6M
Insulin Specific T and B cells in Type 1 DiabetesDP3DK110845 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI CAMBIER, JOHN C, MICHELS, AARON W · 2016 to 2016
$1.7M
Autoantigens targeted by CD8 T cells in type 1 diabetes: from islets to bloodR56DK099317 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI MICHELS, AARON W, NAKAYAMA, MAKI · 2019 to 2019
$194k
MULTIPLE AUTOANTIGENS OF PRETYPE I DMR37DK032083 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI EISENBARTH, GEORGE S · 1992 to 1999
–
NIDDK NIH HHS DP3 DK110845NIDDK NIH HHS P30 DK116073NIDDK NIH HHS R01 DK032083NIDDK NIH HHS R01 DK032493NIDDK NIH HHS R01 DK099317NIDDK NIH HHS R01 DK108868NIDDK NIH HHS R37 DK032083NIDDK NIH HHS R37 DK032493NIDDK NIH HHS R56 DK099317
6 · The paper itself

Abstract

T cells are an integral component of the adaptive immune response via the recognition of peptides by the cell surface-expressed T cell receptor (TCR). Rearrangement of the TCR genes results in a highly polymorphic repertoire on the T cells within a given individual. Although the diverse repertoire is beneficial for immune responses to foreign pathogens, recognition of self-peptides by T cells can contribute to the development of autoimmune disorders. Increasing evidence supports a pathogenic role for T cells in autoimmune pathology, and it is of interest to determine the TCR repertoires involved in autoimmune disease development. In this review, we summarize methodologies and advancements in the TCR sequencing field and discuss recent studies focused on TCR sequencing in a variety of autoimmune conditions. The rapidly evolving methodology of TCR sequencing has the potential to allow for a better understanding of autoimmune disease pathogenesis, identify disease-specific biomarkers, and aid in developing therapies to prevent and treat a number of these disorders.

Indexed as

autoimmunityHLAMHCT cell receptorTCR sequencing

Identifiers

PMID33364626
PMCPMC7757640
OpenAlexW3112320876

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.